New Treatment Paradigms in Primary Biliary Cholangitis (PBC)-New Treatment Paradigms in Primary Biliary Cholangitis (PBC)

Video Transcription

Video Summary

David Assise and Craig Lambert, both adult hepatologists, discuss recent advancements in the treatment of primary biliary cholangitis (PBC). They highlight the FDA's recent approval of two new second-line agents—Elifibranor and Celadelpar—marking a significant shift in PBC treatment. These PPAR agonists are intended for patients who do not respond adequately to the first-line treatment, ursodiol (UDCA). They review the efficacy of these drugs based on clinical trials, indicating substantial improvements in biochemical markers and reductions in pruritus, particularly with Celadelpar. They also discuss the potential for these drugs to improve patients' quality of life. The segment underscores the importance of understanding drug interactions, monitoring adverse effects, and addressing special populations such as pregnant or breastfeeding women. Furthermore, they discuss the potential for combining these treatments with other therapies to improve patient outcomes, emphasizing the evolving nature of PBC treatment goals and strategies.

Keywords

Primary Biliary Cholangitis

autoimmune liver diseases

treatment paradigms

second-line agents

Ursodeoxycholic Acid

PPAR agonists

triple therapy

Elifibranor

Celadelpar

Ursodiol

Clinical trials

Drug interactions